EGFR and breast adenocarcinoma: Given this perspective, gemcitabine-(C4-amide)-[anti-EGFR] and epirubicin-(C3-amide)-[anti-HER2/neu] were applied simultaneously in a dual-combination to detect their potential to evoke additive or synergistic levels of anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3).